Oxytocin-based therapeutics to improve cognitive control in individuals with attention-deficit / hyperactivity disorder

WO2025245322A1PCT designated stage Publication Date: 2025-11-27THE GENERAL HOSPITAL CORP
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/030536
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-22
Filing Date
2025-05-22
Publication Date
2025-11-27

AI Technical Summary

Technical Problem

Current treatments for attention-deficit/hyperactivity disorder (ADHD) have low adherence and do not effectively address impaired cognitive control, which is linked to dysfunction of the frontostriatal neurocircuitry.

Method used

Nasal administration of oxytocin-based therapeutics, including oxytocin and its analogs, to improve cognitive control in individuals with ADHD, administered as a nasal spray in doses of 10-50 IU, optionally 20-30 IU, once, twice, or three times a day, or as needed, potentially combined with conventional treatments.

Benefits of technology

Intranasal oxytocin administration significantly enhances proactive cognitive control and reduces unwanted behavioral impulses in ADHD individuals, as demonstrated by improved performance in cognitive control tasks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000017_0000
    Figure 00000017_0000
  • Figure 00000017_0001
    Figure 00000017_0001
Patent Text Reader

Abstract

Described herein is the use of nasally-administered oxytocin-based therapeutics to improve cognitive control in individuals with attention-deficit / hyperactivity disorder (ADHD).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Oxytocin compositions and methods of use

    US20200316162A1

  • Methods for treating neurodevelopmental disorders

    US20220313650A1